|
Memórias do Instituto Oswaldo Cruz
Fundação Oswaldo Cruz, Fiocruz
ISSN: 1678-8060 EISSN: 1678-8060
Vol. 90, Num. 6, 1995, pp. 683-686
|
Memorias do Instituto Oswaldo Cruz
Vol. 90(6), Nov./Dec. 1995
V3 Peptide Binding Pattern and HIV-1 Transmission Route in
Rio de Janeiro
Monica E Pinto+, Mauro Schechter
Servito de Doencas Infecciosas e Parasitbetarias,
Laboratorio de Pesquisas em AIDS, Hospital Universitbetario
Clementino Fraga Filho, Universidade Federal do Rio de
Janeiro, Av. Brigadeiro Trompowsky s/no, 21941-590 Rio de
Janeiro, RJ, Brasil
Code Number: OC95138
Size of Files:
Text:
No associated graphics files
To characterize antibody binding to a panel of V3 loop
peptides representing diverse HIV-1 neutralization epitopes,
149 HIV-1 infected individuals from Rio de Janeiro (RJ) were
investigated. Results were analyzed with respect to risk
factors for infection and other epidemiological and clinical
data. Peptide reactivity was not associated with sex, clinical
status, CD4 counts, antigenemia or b2-microglobulin serum
level. A segregation of peptide reactivity according to route
of infection was encountered. This finding suggests that more
then one viral strain may be circulating in RJ, in subjects
with different risk factors for HIV-1 infection. An
investigation of prevalent HIV-1 genotypes, serotypes and
immunotypes may be of importance for the design and selection
of potential vaccines to be used in Brazil as well as for the
selection of populations to be included in future vaccine
efficacy trials.
Key words: HIV - AIDS - V3 loop - antigenic variation -
Brazil
Human Immunodeficiency Virus type-1 (HIV-1) shows a high
degree of genetic and antigenic polymorphism. Variability has
been described between isolates from different geographic
areas (Cheingsong-Popov et al. 1992) and within infected
individuals during the course of infection (Holmes et al.
1992, Korber et al. 1992). Genetic diversity between HIV-1
isolates is not uniformly distributed along the viral genome,
being more prominent within certain regions of the external
envelope glycoprotein (hypervariable regions V1-V4 of gp120).
The HIV-1 principal neutralizing determinant (PND) is situated
in the third hypervariable domain (V3 loop) of gp120 (Rusche
et al. 1988). The V3 loop is an important epitope for
neutralization, viral tropism, host range and syncytium
inducing capability (Cann et al. 1992). An epitope localized
at its tip acts as the major binding site for type-specific
neutralizing antibodies (Gouldsmit et al. 1988), and anti-V3
loop antibodies possess protective capabilities (Neurath et
al. 1991).
Enzyme immunoassays based on synthetic peptides derived from
known V3 loop sequences have been developed. The existence of
serologic diversity and its geographic distribution have been
demonstrated (Cheingsong-Popov et al. 1992). In a study in
Thailand, results obtained suggest that peptide based assays
are able to discriminate by serum reactivity between two
genotypes in HIV-1 infected individuals (Pau et al. 1993). In
another study utilizing sera obtained in several countries, it
was demonstrated that serum reactivity to different peptides
correlates with major phylogenetic subgroups (Cheingsong-Popov
et al. 1994). Thus, albeit subject to limitations (Moore et
al. 1994), available data indicate that investigation of
seroreactivity to synthetic peptides might be a rapid,
easy-to-perform and relatively inexpensive epidemiologic tool
for the investigation of circulating viral strains
(Cheingsong-Popov et al. 1992, 1994).
To investigate and characterize serum binding to peptides
representing diverse HIV-1 V3 neutralization epitopes, serum
samples (n=149) were collected between August and December,
1991, from outpatients attending a prospective cohort study of
HIV-infection in Rio de Janeiro (RJ). One hundred and thirty
four subjects acquired HIV infection through sexual
intercourse, and 15 reported parenteral risk factors (IV drug
use or blood transfusion). The clinical stage for each subject
was determined using the WHO staging system (WHO 1986).
Lymphocyte subset determination (CD4 and CD8) was performed by
FACScan (Becton-Dickinson, USA). Serum b2-microglobulin
(Pharmacia Diagnostics, Sweden), and p24 antigen after acid
hydrolysis (Coulter, USA) were also measured. In addition, for
comparison purposes, sera from HIV-1 infected subjects from
the United States of America (USA) (n=105) and the United
Kingdom (UK) (n=103) were also analyzed.
Reactivity to V3 loop peptides (MN, HXB2, Z3, Z321, Z6, and
MAL) was assessed by EIA (Cheingsong-Popov et al. 1992). Of
the Brazilian sera, 102 (68.5%) reacted to MN, 43 (28.9%) to
Z3, 18 (12.1%) to HXB2, 19 (12.1%) to Z321, 16 (10.7%) to MAL,
10 (6.7%) to Z6, whereas 35 (23.5%) did not react with any of
the peptides tested. HIV-1 Western Blot was performed with all
35 peptide-negative samples and 30/35 (87%) of the sera
reacted to gp160 and/or gp120 antigens. The remaining 5 sera
were HIV-1 Western Blot positive on the grounds of gp41, pol
and/or gag reactivity, but did not react either with gp160 and
gp120. HIV-1 PCR on the pol gene was undertaken, and was
positive in all five patients.
Sera were then analyzed according to the subjects' probable
route of infection, sexual or parenteral. The distribution of
antibody reactivity to the MN V3 peptide was analyzed, and
compared to the distribution in subjects from the UK and USA.
Differences in MN reactivity in sera from subjects from RJ
were demonstrated, in relation to route of transmission. In
the sexual transmission group, 86/134 (64%) subjects had
binding antibodies to the MN peptide. In the parenteral group,
14/15 (93%) sera were MN reactive (p < 0.03, 2-tailed
FisherAEs exact test). In contrast, 99-100% of all sera from
HIV-1 infected subjects from the UK and the USA had binding
antibodies to the MN V3 peptide (Cheingsong-Popov et al.
1992). Peptide reactivity was not associated with sex,
clinical status, CD4 counts, antigenemia or b2-microglobulin
serum level.
In summary, 68.5% of the Brazilian sera tested reacted to the
MN peptide, a distribution of binding antibodies that differs
greatly from that seen with North American and European sera.
Similar results have been previously described (Carrow et al.
1991, Bongertz et al. 1994). In addition, over 35% of the
Brazilian sera tested (109/296) did not react to any of the
peptides, although the great majority of the negative sera did
contain detectable antibodies to env products, gp160/120. In
previous studies, utilizing sera from several countries, all
sera tested were found to contain antibodies to at least one
of the peptides of this panel (Cheingsong-Popov et al. 1992).
A segregation of peptide reactivity according to route of
infection was encountered. This finding suggests that more
then one viral strain may be circulating in RJ, in subjects
with different risk factors for infection, similar to that
which has been described in Thailand (Pau et al. 1993). In
fact, sequence analysis of the V3 loop of Brazilian isolates
has indicated the heterogeneity of the viral strains
circulating in Brazil (Potts et al. 1993, Morgado et al. 1994,
Janini et al. unpublished data). HIV-1 V3 sequences have been
further analyzed in a phylogenetic tree analysis and some
isolates have been shown to belong to a new F subgroup
(Morgado et al. 1994). However, there are no substantial
studies to correlate the genotypes of HIV-1 variants from
Brazil, their antigenicity and antibody response. Our
serological data on V3 peptide binding support the
heterogeneous sequence data, further strengthening the study
of genetic diversity, by providing confirmation on antigenic
diversity. An investigation of HIV-1 V3 genotypes, serotypes
and immunotypes in Brazil will be important for the design and
selection of potential vaccines to be used in Brazil as well
as for the selection of populations to be included in future
vaccine efficacy trials. This type of serological screening
may allow population based studies of HIV-1 diversity to be
undertaken, and to point to populations where more detailed
sequencing information may be of most value.
ACKNOWLEDGEMENTS
To Prof Jonathan Weber and Dr Cheingsong-Popov for the
provision of peptides and for helpful discussions.
REFERENCES
Bongertz V, Jansson M, Flodby P, Morgado MG, Galvpio-Castro B,
Wigzell H 1994. Analysis of antibody reactivity specificity
against the third variable region of the envelope glycoprotein
gp120 of HIV-1 in plasma from HIV-1-positive individuals
residing in Brazil. Braz J Med Biol Res 27: 1225-1236.
Cann AJ, Churter MJ, Boyd M, OAE Brien W, Zhao JQ, Zack J,
Chen IS 1992. The region of the envelope gene of human
immunodeficiency virus type 1 responsible for determination of
cell tropism. J Virol 66: 305-309.
Carrow EW, Vujcic LK, Glass WL, Seamon KS, Rastogi SR, Hendry
M, Boulos R, Nzila N, Quinnan-Jr Q 1991. High prevalence of
antibodies to the gp120 V3 region principal neutralizing
determinant of HIV-1MN in sera from Africa and the Americas.
AIDS Res Human Retrovirus 7: 831-838.
Cheingsong-Popov R, Callow D, Beddows S, Shaunak S, Wasi C,
Kalebu P, Gilks CF, Petrascu IV, Garaev MM, Watts DM,
Constantine NT, Weber JN 1992. Geographic diversity of human
immunodeficiency virus type 1: serologic reactivity to env
epitopes and relationship to neutralization. J Infect Dis 165:
256-261.
Cheingsong-Popov R, Lister S, Callow D, Kaleebu P, Beddows S,
Weber JN 1994. Serotyping HIV-1 through antibody binding to
the V3 loop: relationship to viral genotype. AIDS Res Hum
Retrovirus (in press).
Gouldsmit J, Debouck C, Meloen RH, Smit L, Bakker M, Asher DM,
Wolff AV, Gibbs-Jr CJ, Gajdousek DC 1988. Human
immunodeficiency virus type 1 neutralization epitope with
conserved architecture elicits early type-specific antibodies
in experimentally infected chimpanzees. Proc Natl Acad Sci USA
85: 4478-4482.
Holmes EC, Zhang LQ, Simmonds P, Ludlam CA, Brown AJ 1992.
Convergent and divergent sequence evolution in the surface
envelope glycoprotein of human immunodeficiency virus type 1
within a single infected patient. Proc Natl Acad Sci USA 89:
4935-4939.
Korber B, Wolinsky S, Haynes B, Kunstman K, Levy R, Furtado M,
Otto P, Myers G 1992. HIV-1 intrapatient sequence diversity
in the immunogenic V3 region. AIDS Res Human Retrovirus 8:
1461-1465.
Moore JP, Cao Y, Conley AJ, Wyatt R, Robinson J, Gorny MK,
Zolla-Pazner S, Ho D, Koup RA 1994. Studies with monoclonal
antibodies to the V3 region of HIV-1 gp120 reveal limitations
to the utility of solid-phase peptide binding assays. J Acq
Immun Def Synd 7: 332-339.
Morgado MG, Sabino EC, Sphaer EG, Bongertz V, Brigido L,
Guimarpies MD, Castilho EA, Galvpio-Castro B, Mullins J,
Hendry RM, Mayer A 1994. V3 Region Polymorphism in HIV-1 from
Brazil: Prevalence of Subtype B Strains Divergent from North
American/European Prototype and Detection of Subtype f. aids
res hum retrovirus 10: 569-576.
Neurath Ar, Jiang S, Strick N, Kolbe H, Kieny MP, Muchmore E,
Girard M 1991. Antibody responses of chimpanzees immunized
with synthetic peptides corresponding to full-length V3
hypervariable loops of HIV-1 envelope glycoproteins. AIDS Res
Hum Retrovirus 7: 813-823.
Pau C-P, Lee-Thomas S, Aunawit W, George JR, Ou C-Y, Parekh
BS, Granade TC, Holloman DL, Phillips S, Schochetman G, Young
NL, Takebe Y, Gayle HD, Weniger BG 1993. Highly specific
V3-peptide enzyme immunoassay for serotyping HIV-1 specimens
from Thailand. AIDS 7: 337-340.
Potts KE, Kalish ML, Lott T, Orloff, Luo CC, Bernard MA, Alves
CB, Badaro R, Suleiman J, Ferreira O, Shochetman G, Johnson-Jr
WD, Ou C-Y 1993. Genetic heterogeneity of the V3 region of the
HIV-1 envelope glycoprotein in Brazil. AIDS 7: 1191-1198.
Rusche Jr, Javaherian K, Mcdanal C, Petro J, Lynn DL, Grimaila
R, Langlois A, Gallo RC, Arthur LO, Fischinger PJ, Bolognesi
DP, Putney SD, Matthews TJ 1988. Antibodies that inhibit
fusion of human immunodeficiency virus-infected cells bind a
24-amino acid sequence of the viral envelope gp120. Proc Natl
Acad sci USA 85: 3198-3202.
WHO 1986. Acquired Immunodeficiency Syndrome
(AIDS),WHO/CDC/Case definition for AIDS. Weekly
Epidemiological Record 61: 69-73.
This work was partially supported by a grant from Petrobrbetas
SA
+ Corresponding author
Received 16 January 1995
Accepted 9 June 1995
Copyright 1995 Fundacao Oswaldo Cruz, FIOCRUZ
|